Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 270-192-0 | CAS number: 68412-48-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://chesar.echa.europa.eu/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Endpoint summary
Administrative data
Description of key information
Acute Toxicity: Oral
LD50 > 2000 mg/kg bw in female CRL:(WI) rats.
Acute Toxicity: Dermal
LD50 > 2000 mg/kg bw in female CRL: (WI) rats.
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 20 June 2017 to 05 July 2017
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
- Version / remarks:
- OECD GUIDELINES FOR TESTING OF CHEMICALS (423, adopted at 17th Dec. 2001)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.1 tris (Acute Oral Toxicity - Acute Toxic Class Method)
- Version / remarks:
- Commission Regulation (EC) No 440/2008 of 30 May 2008, B.1.tris
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.1100 (Acute Oral Toxicity)
- Version / remarks:
- EPA Health Effects Test Guidelines (OPPTS 870.1100), United States, EPA 712-C-98-190 (1998)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- acute toxic class method
- Limit test:
- yes
- Specific details on test material used for the study:
- No further details specified in the study report.
- Species:
- rat
- Strain:
- Wistar
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- Species and strain: CRL:(WI) Wistar rats
Source: Charles River Laboratories, Research Models and Services, Germany GmbH, Sandhofer Weg 7, D-97633 Sulzfeld
Hygienic level at arrival: SPF
Hygienic level during the study: Standard housing conditions
Number of animals: 6 animals
Sex: Female, nulliparous and non-pregnant
Age of animals at dosing: Young healthy adult rats, 9 weeks old
Body weight at treatment: 203 – 232 g
Acclimatization period: at least 12 days
Husbandry
Animal health: Only healthy animals were used for the test. The Veterinarian certified health status.
Number of animal room: 522/9
Housing: 3 animals / cage
Cage type: Type II polypropylene/polycarbonate
Bedding/Nesting: “Lignocel 3/4-S Hygienic Animal Bedding” and “Arbocel crinklets natural” nest building material produced by J. Rettenmaier & Söhne GmbH & Co.KG (D-73494 Rosenberg, Germany) were available to animals during the study.
Lighting period: 12 hours daily, from 6.00 am to 6.00 pm
Temperature: 22 ± 3 °C
Relative humidity: 30-70%
Ventilation: 15 – 20 air exchanges/hour
Enrichment: Animals were housed by group to allow social interaction and with deep wood sawdust bedding to allow digging and other normal rodent activities.
The temperature and relative humidity were recorded twice daily during the study.
Food and Water Supply
Animals received ssniff® SM R/M "Autoclavable complete diet for rats and mice – breeding and maintenance" produced by ssniff Spezialdiäten GmbH, D-59494 Soest, Germany (Batch no.: 285 17890, expiry date: 30 August 2017), ad libitum, and tap water from the municipal supply, as for human consumption from 500 ml bottles, ad libitum. The food is considered not to contain any contaminants that could reasonably be expected to affect the purpose or integrity of the study.
Water quality control analysis is performed once every three months and microbiological assessment is performed monthly, by Veszprém County Institute of State Public Health and Medical Officer Service (ÁNTSZ, H-8201 Veszprém, József A.u.36., Hungary).
Animal Identification
Animals were individually identified using numbers written on the tail with an indelible marker pen. The numbers were given on the basis of CiToxLAB Hungary Ltd.'s Master File, for each animal allocated to the treatment groups. The cages were identified by cards, with information about study code, sex, dose group, cage number and individual animal numbers. - Route of administration:
- oral: gavage
- Vehicle:
- DMSO
- Details on oral exposure:
- Formulation
The test item was freshly formulated at a concentration of 200 mg/mL in the vehicle, in the Pharmacy of CiToxLAB Hungary Ltd. on the day of administration. The formulation container was stirred continuously up to finishing the treatment.
Vehicle Selection
The selection of the vehicle was made during trial formulations with the test item. The final choice of vehicle was approved by the Sponsor.
On the basis of the trial formulations with the test item, the vehicle used was DMSO.
Vehicle: Dimethyl sulfoxide (DMSO)
Batch number: STBG8411
Expiry date: 29 February 2020
Dose volume: 10 mL/kg bw
Justification of the dose:
A limit of 2000 mg/kg bw dose was selected by the Sponsor.
Initially, three females (assigned to Group 1) were treated at a dose level of 2000 mg/kg bw. The test item did not cause mortality in this group and a second group (Group 2) was treated at the same dose level. No mortality was observed in the confirmatory group, therefore no further testing was required according to OECD 423 and Commission Regulation (EC) No 440/2008 of 30 May 2008, B.1.tris. - Doses:
- A limit of 2000 mg/kg bw dose was selected by the Sponsor.
- No. of animals per sex per dose:
- Initially, three females (assigned to Group 1) were treated at a dose level of 2000 mg/kg bw. The test item did not cause mortality in this group and a second group (Group 2) was treated at the same dose level.
- Control animals:
- no
- Details on study design:
- Procedure
A single oral gavage administration was followed by a 14-day observation period. On the night before treatment, the animals were fasted. The food but not water was withheld during an overnight period. Animals were weighed just before treatment. The test item was administered by oral gavage in the morning. The food was made available again at about 3 hours after the treatment.
OBSERVATIONS
Clinical Observations
Clinical observations were performed at 30 minutes, 1, 2, 3, 4 and 6 hours after dosing and daily for 14 days thereafter, as applicable. Individual observations were performed on the skin, fur, eyes, mucous membranes, respiratory, circulatory, autonomic and central nervous system, somatomotor activity and behaviour pattern. Particular attention was directed to observation of tremors, convulsions, salivation, diarrhoea, lethargy, sleep and coma.
Body Weight Measurement
The body weight was recorded on the day before treatment (Day -1), on the day of the treatment (Day 0), Day 7 and Day 14.
NECROPSY
All animals were subjected to a necropsy and a macroscopic examination. The animals were exsanguinated after verification of narcosis following an injection of pentobarbital sodium (Release; Lot No.: 106075, Expiry Date: July 2018, Produced by: Wirtschaftsgenossenschaft deutscher Tierärzte eG, Siemensstr. 14, 30827 Garbsen, Germany). After examination of the external appearance, the cranial, thoracic and abdominal cavities were opened and the appearance of the tissues and organs were observed. All gross macroscopic changes were recorded for each animal. - Statistics:
- Not specified.
- Key result
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- AMINOX® did not cause mortality at a dose level of 2000 mg/kg bw.
- Clinical signs:
- other: Clinical signs were observed in 3/6 animals treated at the dose level of 2000 mg/kg bw with AMINOX® which included hunched back. There was no other test item related effects on the animals.
- Gross pathology:
- There was no evidence of the macroscopic observations at necropsy at a dose level of 2000 mg/kg bw.
- Other findings:
- No further findings detailed in the study report.
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- Under the conditions of this study, the acute oral LD50 value of the test item AMINOX® was found to be above 2000 mg/kg bw in female CRL:(WI) rats.
- Executive summary:
The single-dose oral toxicity of AMINOX® was performed according to the acute toxic class method (OECD 423 and Commission Regulation (EC) No 440/2008 of 30 May 2008, B.1.Tris) in CRL:(WI) rats.
Initially, three females (assigned to Group 1) were treated at a dose level of 2000 mg/kg bw. The test item did not cause mortality in this group and a second group (Group 2) was treated at the same dose level. No mortality was observed in the confirmatory group, therefore no further testing was required according to OECD 423 and Commission Regulation (EC) No 440/2008 of 30 May 2008, B.1.tris.
A single oral treatment was carried out by gavage for each animal after an overnight food withdrawal. Food was made available again 3 hours after the treatment. The test item was administered formulated in Dimethyl sulfoxide (DMSO) at a concentration of 200 mg/mL at a dosing volume of 10 mL/kg bw.
Clinical observations were performed at 30 minutes, 1, 2, 3, 4 and 6 hours after dosing and daily for 14 days thereafter. Body weight was measured on Days -1, 0 and 7 and Day 14.
All animals were subjected to a necropsy and a macroscopic examination.
Results
Mortality
AMINOX® did not cause mortality at a dose level of 2000 mg/kg bw.
Clinical Observations
Clinical signs were observed in 3/6 animals treated at the dose level of 2000 mg/kg bw with AMINOX® which included hunched back. There was no other test item related effects on the animals.
Body Weight and Body Weight Gain
One animal at dose level 2000 mg/ kg bw (No: 9632) showed a reduced body weight gain in the second week of the observation period. This change was considered incidental and not ascribed to treatment. There was no other treatment related effects on body weight or body weight gain during the observation period.
Macroscopic Findings
There was no evidence of the macroscopic observations at necropsy at a dose level of 2000 mg/kg bw.
Conclusion:
Under the conditions of this study, the acute oral LD50 value of the test item AMINOX® was found to be above 2000 mg/kg bw in female CRL:(WI) rats.
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 3 (not reliable)
- Rationale for reliability incl. deficiencies:
- other: Study was not conducted in accordance to GLP or recognised guidelines
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 401 (Acute Oral Toxicity)
- GLP compliance:
- no
- Test type:
- other:
- Limit test:
- yes
- Species:
- rat
- Strain:
- Long-Evans
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- Not specified
- Route of administration:
- oral: unspecified
- Vehicle:
- other: methylcellulose
- Details on oral exposure:
- Prior to oral exposure rats were fasted for 24 hours
- Doses:
- Single oral dose of 5 g/kg on day 1
- No. of animals per sex per dose:
- 5 male and 5 female rats were each dosed with 5 g/kg of the test substance
- Control animals:
- not specified
- Details on study design:
- A group of ten Long Evans rats (5 male and 5 female) weighing 200 – 250 g were fasted for 24 hours and given AMINOX C#4711 at 5 g/kg orally. The test material was administered as a suspension in 0.25% methylcellulose at a volume of 10 ml/kg. The rats were observed for mortality for 14 days
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 5 000 mg/kg bw
- Mortality:
- None
- Clinical signs:
- other: None clinical signs specified
- Gross pathology:
- Not specified
- Other findings:
- No other findings
- Interpretation of results:
- not classified
- Remarks:
- Migrated information Criteria used for interpretation of results: other: Section 191.1(b) (1) of the Federal Hazardous Substances Act.
- Conclusions:
- AMINOX C#4711 would not be a toxic substance according to section 191.1(b) (1) of the Federal Haze- Substances Act (LD50 > 5 g/kg)
- Executive summary:
The aim of the study was to assess the toxicity potential of Aminox C#4711 via the oral route. 10 rats (5 male and 5 female) were administered Aminox C#4711 5 g/kg orally on day 1 and observed for 14 days. None of the rats died during the 14 day period and necropsy did not reveal any visable drug related lesions. Therefore it can be concluded that the acute oral toxicity of Aminox C#4711 is LD50 > 5g/kg and is not considered toxic according to section 191.1(b) (1) of the Federal Haze-Susbtances Act.
Results from the study concluded that Aminox C#4711 is not considered a toxic substance as none of the treated rats died during the 14 day perood of observation. Necropsy also revealed that there was no visible test substance related lesion. Therefore the acute oral LD50 > 5g/kg
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 4 (not assignable)
- Rationale for reliability incl. deficiencies:
- other: Study was not conducted in accordance with GLP or a recognised test guideline
- Qualifier:
- no guideline available
- GLP compliance:
- no
- Remarks:
- Predates GLP
- Test type:
- other:
- Limit test:
- yes
- Species:
- rat
- Strain:
- not specified
- Sex:
- not specified
- Details on test animals or test system and environmental conditions:
- All animals were housed in metal cages with raised wire mesh floors, food and water were available at all times.
- Route of administration:
- oral: unspecified
- Vehicle:
- other: Distilled water
- Details on oral exposure:
- Animals were force fed test substance which was suspended in distilled water.
- Doses:
- Single dose of 400mg (equivalent of 1.69 g/kg/bw) on day 1
- No. of animals per sex per dose:
- Not specified
- Control animals:
- not specified
- Details on study design:
- Distilled water suspension of the samples in various amounts were made and force fed to adult albino rats, in an attempt to determine the minimum amount of the sample which could cause death within 3 days.
- Statistics:
- None
- Sex:
- not specified
- Dose descriptor:
- LD50
- Effect level:
- > 1 690 mg/kg bw
- Based on:
- test mat.
- Mortality:
- None
- Clinical signs:
- other: Not specified
- Gross pathology:
- Not specified
- Other findings:
- Not specified
- Interpretation of results:
- other: Inconclusive
- Remarks:
- Criteria used for interpretation of results: not specified
- Conclusions:
- Minimum leath dose was not obtained. 400mg (equivalent to 1.69 g/kg/bw) was force fed to several rats but surivived the 3 day study period.
- Executive summary:
Study was conducted on albino rats to determine the minimum lethal dose of Aminox A-3250. The maximum amount of test substance that was administered to several rats was 400 mg (equivalent to 1.69 g/kg/bw). All rats survived the 3 day study period, LD50 > 1.69 g/kg/bw.
Referenceopen allclose all
CLINICAL OBSERVATIONS
DOSE LEVEL: 2000 mg/kg bw, Treatment on Day 0 SEX: FEMALE
Cage No. |
Animal Number |
Observations |
Observation days |
Frequency |
||||||||||||
0 |
1 |
2 |
3 |
4 |
5 |
6 |
7-14 |
|||||||||
30’ |
1h |
2h |
3h |
4h |
6h |
|||||||||||
1 |
9631 |
Symptom free |
+ |
+ |
- |
- |
- |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
17/20 |
Hunched back |
- |
- |
+ |
+ |
+ |
- |
- |
- |
- |
- |
- |
- |
- |
3/20 |
||
9632 |
Symptom free |
+ |
+ |
- |
- |
- |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
17/20 |
|
Hunched back |
- |
- |
+ |
+ |
+ |
- |
- |
- |
- |
- |
- |
- |
- |
3/20 |
||
9633 |
Symptom free |
+ |
+ |
- |
- |
- |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
17/20 |
|
Hunched back |
- |
- |
+ |
+ |
+ |
- |
- |
- |
- |
- |
- |
- |
- |
3/20 |
||
2 |
9634 |
Symptom free |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
20/20 |
9635 |
Symptom free |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
20/20 |
|
9636 |
Symptom free |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
20/20 |
Remarks: + = present - = absent
h = hour ‘ = minute
Frequency of observations = number of occurrence of observation / total number of observations
BODY WEIGHT DATA
DOSE LEVEL: 2000 mg/kg bw, Treatment on Day 0 SEX: FEMALE
Cage No. |
Animal Number |
Body weight (g) Days |
Body Weight Gain (g) |
||||||
-1 |
0 |
7 |
14 |
-1-0 |
0-7 |
7-14 |
-1-14 |
||
1 |
9631 |
243 |
227 |
235 |
250 |
-16 |
8 |
15 |
7 |
9632 |
233 |
217 |
233 |
231 |
-16 |
16 |
-2 |
-2 |
|
2633 |
239 |
227 |
237 |
243 |
-12 |
10 |
6 |
4 |
|
2 |
9634 |
241 |
232 |
240 |
261 |
-9 |
8 |
21 |
20 |
9635 |
212 |
203 |
227 |
239 |
-9 |
24 |
12 |
27 |
|
9636 |
220 |
207 |
230 |
247 |
-13 |
23 |
17 |
27 |
|
Mean: |
231.3 |
218.8 |
233.7 |
245.2 |
-12.5 |
14.8 |
11.5 |
13.8 |
|
Standard deviation: |
12.6 |
11.8 |
4.7 |
10.2 |
3.1 |
7.3 |
8.3 |
12.5 |
NECROPSY FINDINGS
DOSE LEVEL: 2000 mg/kg bw, Treatment on Day 0 SEX: FEMALE
Cage No. |
Animal Number |
Necropsy Date/ Necropsy Day |
External Observations |
Internal Observations |
Organ/Tissue |
1 |
9631 |
04 July 2017 Day 14 |
No external observations recorded |
No internal observations recorded |
Not applicable |
9632 |
04 July 2017 Day 14 |
No external observations recorded |
No internal observations recorded |
Not applicable |
|
9633 |
04 July 2017 Day 14 |
No external observations recorded |
No internal observations recorded |
Not applicable |
|
2 |
9634 |
05 July 2017 Day 14 |
No external observations recorded |
No internal observations recorded |
Not applicable |
9635 |
05 July 2017 Day 14 |
No external observations recorded |
No internal observations recorded |
Not applicable |
|
9636 |
05 July 2017 Day 14 |
No external observations recorded |
No internal observations recorded |
Not applicable |
None of the treated rats died during the fourteen day period of observation. Necropsy upon termination of the study revealed no visible drug related lesions.
400mg (equivalent to 1.69 g/kg/bw) was force fed to several rats but surivived the 3 day study period.
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 2 000 mg/kg bw
- Quality of whole database:
- K1
Acute toxicity: via inhalation route
Link to relevant study records
- Endpoint:
- acute toxicity: inhalation
- Data waiving:
- study scientifically not necessary / other information available
- Justification for data waiving:
- other:
Reference
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 4 (not assignable)
- Rationale for reliability incl. deficiencies:
- other: Study not conducted in accordance with GLP or a recognised test guideline
- Qualifier:
- according to guideline
- Guideline:
- other: Section 162.8 (c) of Regulation for the Enforcement of Federal Insecticide, Fungicide and Rodenticide Acte, United States Dept. of Agriculture. March 1948
- GLP compliance:
- no
- Remarks:
- Predates GLP
- Test type:
- other:
- Limit test:
- no
- Species:
- rabbit
- Strain:
- not specified
- Sex:
- not specified
- Details on test animals or test system and environmental conditions:
- Not specified in report
- Type of coverage:
- occlusive
- Vehicle:
- other: Distilled water
- Duration of exposure:
- Exposure of 24 hours.
- Doses:
- 200mg/kg/bw
- No. of animals per sex per dose:
- 10
- Control animals:
- not specified
- Details on study design:
- The hair from one side of the rabbit was removed using OIster small animal clipper model #2. The submitted samples were tested at a dosage of 200 mg/kg/bw.
The calculated dosage was wetted with distilled water and then placed onto gauze squares measuring 2 x 4 inches and two layers in thickness. The squares were immediately placed on the bare skin of each rabbit and securely help in place with waterproof adhesive tape. Care was taken to completely cover each patch securely so as to minimize evaporation and to ensure continuous contact with the base skin for 24 hours. Additional observations were made after 72 hours. - Sex:
- not specified
- Dose descriptor:
- LD50
- Effect level:
- > 200 mg/kg bw
- Based on:
- test mat.
- Mortality:
- None
- Clinical signs:
- other: None
- Gross pathology:
- No data
- Other findings:
- None
- Interpretation of results:
- practically nontoxic
- Remarks:
- Migrated information Criteria used for interpretation of results: not specified
- Conclusions:
- All animals survived the 24 hours test period and remained alive and well. There were no toxic manifestations exhibited by any animal under the conditions of the study.
- Executive summary:
The aim of the study was to determine whether Aminox A-3520 is toxic via the dermal absorption. The test was conducted in accordance to Section 162.8 (c) of Regulation for the Enforcement of Federal Insecticide, Fungicide and Rodenticide Acte, United States Dept. of Agriculture. March 1948. All animals survived the 24 hours test period and remained alive and well, not showing any signs of toxicity. To conclude Aminox A-3520 was not deemed to be toxic via the dermal route and the LD50 > 200 mg/kg/bw
- Endpoint:
- acute toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 13 - 29 November 2018
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 402 (Acute Dermal Toxicity)
- Deviations:
- yes
- Remarks:
- Due to technical oversight the environmental parameters were recorded only once on 10 November 2018.
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.3 (Acute Toxicity (Dermal))
- Deviations:
- yes
- Remarks:
- Due to technical oversight the environmental parameters were recorded only once on 10 November 2018.
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.1200 (Acute Dermal Toxicity)
- Deviations:
- yes
- Remarks:
- Due to technical oversight the environmental parameters were recorded only once on 10 November 2018.
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- standard acute method
- Limit test:
- no
- Specific details on test material used for the study:
- Name: AMINOX®
Chemical name: 2-Propanone, reaction products with diphenylamine
CAS number: 68412-48-6
Batch/Lot Number: T7C16001
Description: Green to brown flakes
Purity: 100% (as a UVCB)
Expiry date: 14 March 2019
Storage conditions: Controlled room temperature (15-25 ºC, below 70 RH%)
Safety precautions: Routine safety precautions (lab coat, gloves, safety glasses, face mask) for unknown materials were applied to assure personnel health and safety. - Species:
- rat
- Strain:
- Wistar
- Remarks:
- Crl: WIWistar rats
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- Species and strain: Crl: WIWistar rats
Source: Charles River Laboratories, Research Models and Services, Germany GmbH, Sandhofer Weg 7, D-97633 Sulzfeld, Germany
Hygienic level at arrival: SPF
Hygienic level during
the study: Standard housing conditions
Justification of strain: The Wistar rat is one of the standard rodent species used in acute toxicity studies.
Number of animals: 3 animals
Sex: Female, nulliparous and non-pregnant.
Age of animals at study start: ~9 weeks old
Body weight range at dosing: Between 238 g and 246 g
Acclimation time: 5 or 7 days
Husbandry
Animal health: Only healthy animals were used for the study. The staff Veterinarian certified the health status.
Room-Box: 242/3
Housing / Enrichment: Individual and group caging. Rodents were housed with deep wood sawdust bedding to allow digging and other normal rodent activities.
Cage type: Type II. polypropylene/polycarbonate
Bedding: Lignocel 3/4-S Hygienic Animal Bedding (produced by J. Rettenmaier & Söhne GmbH+Co.KG, Germany) was available to animals during the study. The quality of the bedding was guaranteed by the supplier. Details of bedding quality are archived with the raw data.
Nesting: Nest building material Arbocel Crinklets natural (produced by J. Rettenmaier & Söhne GmbH+Co.KG, Germany) was available to animals during the study. The quality of the nest building material was guaranteed by the supplier. Details of nest building material quality are archived with the raw data.
Light: 12 hours daily, from 6.00 a.m. to 6.00 p.m.
Temperature: 19.2–24.2°C
Relative humidity: 33–62%
Ventilation: 15-20 air exchanges/hour
Enrichment: Rodents were housed with deep wood sawdust bedding to allow digging and other normal rodent activities.
Temperature and relative humidity were recorded twice daily during the study.
Food and Water Supply
Animals received ssniff® SM R/M "Autoclavable complete diet for rats and mice – breeding and maintenance" produced by ssniff Spezialdiäten GmbH, D-59494 Soest, Germany, ad libitum, and tap water from the municipal supply, as for human consumption from a 500 mL bottle, ad libitum. The food is considered not to contain any contaminants that could reasonably be expected to affect the purpose or integrity of the study and the water was considered fit for human consumption.
The batch of feed employed in the study was as follows:
• 639 38520, expiry date: 30 April 2019.
The supplier provided an analytical certificate for the batch used. A copy of the certificate will be archived with the raw data.
Water quality control analysis is performed once every three months and microbiological assessment is performed monthly by Veszprém County Institute of State Public Health and Medical Officer Service (ÁNTSZ, H-8201 Veszprém, József A.u.36., Hungary). The quality control results are retained in the archives at Citoxlab Hungary Ltd.
Animal Identification
Animals were individually identified using numbers written on the tail with an indelible pen. The numbers were given on the basis of Citoxlab Hungary Ltd.' s Master File for each animal allocated to the treatment groups. The cages were identified by cards containing information about study code, sex, dose group, cage number and individual animal number. - Type of coverage:
- semiocclusive
- Vehicle:
- unchanged (no vehicle)
- Details on dermal exposure:
- The back of each animal was shaved (approximately 10% area of the total body surface) approximately 24 hours prior to treatment. The test item was applied to the shaved skin as a single dose and remained in contact with the skin for the 24-hour exposure period. Sufficient amount of water was used to moisten the test item to ensure good contact with the skin. Sterile gauze pads were placed on the skin of rats to cover the test item. These gauze pads were kept in contact with the skin using a patch with adhesive hypoallergenic plaster. The entire trunk of the animal was then wrapped with semi occlusive plastic wrap for 24 hours.
At the end of the exposure period, the treated area of skin with the test item was washed with water at body temperature. - Duration of exposure:
- 14 days
- Doses:
- Dose range-finding test
Initially one animal was dosed at the selected limit dose (2000 mg/kg bw). As the animal survived, the second and third animals received the same dose.
Main test
A single dermal application of 2000 mg/kg bw was made and was followed by a 14-day observation period. - No. of animals per sex per dose:
- 3 animals were dosed with 2000 mg/kg bw
- Control animals:
- yes, concurrent no treatment
- Details on study design:
- Observations
Clinical Observations
Clinical observations were performed on the day of treatment at 30 minutes, 1, 2 and 5 hours after application of the test item and once each day for 14 days thereafter. Observations included the skin and fur, eyes and mucous membranes, the respiratory, circulatory, autonomic and central nervous system, somatomotor activity and behaviour pattern. Particular attention was directed to observation of tremors, convulsions, salivation, diarrhoea, lethargy, sleep and coma.
Skin Irritation
Adverse skin reactions at the site of application were recorded daily following the removal of the dressing.
Measurement of Body Weight
The body weights were recorded on Day 0 (before the test item administration) and on Days 7 and 14 (before necropsy).
NECROPSY
Macroscopic examination was performed on all animals. All animals were anaesthetised with sodium pentobarbital (details in 3.3) and exsanguinated. Following confirmation of death, after examination of the external appearance, the cranial, thoracic and abdominal cavities were opened and the appearance of the tissues and organs was observed. All macroscopic changes were recorded.
Formulation
The powdered test item was administered as a single dose without dilution, as supplied by the Sponsor. Sufficient water was used to moisten the test material to ensure good contact with the skin.
Justification of the dose:
In an acute oral toxicity study (study code: 17/174-001P), adverse effects were noted up to 2000 mg/kg bw (hunched back in 3 animals out of 6). Thus in this dermal acute study, one female animal was treated initially at 2000 mg/kg bw in the range finding test followed by 2 more animals treated in the main study. - Key result
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- >= 2 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- The test item did not cause mortality at a dose level of 2000 mg/kg bw.
- Clinical signs:
- other: There were no systemic clinical signs noted in any animal throughout the study.
- Gross pathology:
- There was no evidence of any gross macroscopic changes at a dose level of 2000 mg/kg bw.
- Other findings:
- Local Dermal Signs
No adverse local dermal signs were observed after treatment with the test item or during the 14-day observation period. - Interpretation of results:
- GHS criteria not met
- Conclusions:
- The acute dermal median lethal dose (LD50) of the test item AMINOX® was found to be greater than 2000 mg/kg body weight in female Crl: WI rats.
According to the GHS criteria, AMINOX® can be ranked as "Unclassified" for acute dermal exposure. - Executive summary:
An acute dermal toxicity study was performed with the test item AMINOX® in female Crl: WIWistar rats, in compliance with OECD Guideline No.: 402 (2017), Commission Regulation (EC) No 440/2008, B.3 and OPPTS 870.1200 [1-3].
This study was being performed with vertebrate animals as no in vitro alternative is available. The Sponsor confirmed previously that the specific regulatory purpose of this study did not allow a waiving of this dermal acute study, taking account of the OECD guidance document 237.
The study was designed such that the minimum number of animals were used. One female animal was initially treated at a dose level of 2000 mg/kg body weight (bw) in a range-finding phase. Due to the absence of clinical signs, a further 2 females were then treated to confirm the non-lethal dose level. The test item was applied as a single dermal 24-hour exposure followed by a 14-day observation period.
Clinical observations were performed on all animals at 30 minutes, 1, 2, 5 hours after dosing and daily for 14 days thereafter. Body weight was measured on Day 0 (prior to dosing) and on Days 7 and 14 (before necropsy). Gross macroscopic examination was performed on all animals at necropsy at the end of the 14-day observation period (Day 14).
The results of the study were summarised as follows:
Mortality
The test item did not cause mortality at the dose level of 2000 mg/kg bw.
Systemic clinical signs
There were no systemic clinical signs noted in any animal throughout the study.
Local dermal signs
No adverse local dermal signs were observed after treatment with the test item or during the 14-day observation period.
Body weight and body weight gain
There were no test item related effects on body weight or body weight gain during the observation period. Body weights were within the range commonly recorded for this strain and age.
Necropsy
There was no evidence of any macroscopic changes at a dose level of 2000 mg/kg bw.
Conclusions
The acute dermal median lethal dose (LD50) of the test item AMINOX® was found to be greater than 2000 mg/kg body weight in female Crl: WI rats.
According to the GHS criteria, AMINOX® can be ranked as "Unclassified" for acute dermal exposure.
Referenceopen allclose all
All animals survived the 24 hours test period and remained alive and well. There were no toxic manifestations exhibited by any animal under the conditions of the study.
DOSE LEVEL: 2000 mg/kg bw, Treatment on Day 0
Cage No.
|
Animal Number
|
Observations
|
Observation days
|
Frequency |
|||||||||||||||||
0 |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
14 |
|||||||
30’ |
1h |
2h |
5h |
||||||||||||||||||
1
|
5890
|
Symptom Free
|
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
18/18
|
2 / 1
|
5891
|
Symptom Free
|
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
18/18
|
3 / 1
|
5892
|
Symptom Free
|
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
18/18
|
Remarks: |
+ = present |
h = hour (s) |
' = minute |
Frequency of observation = number of occurrence of observation / total number of observations |
Body Weight DataDOSE LEVEL: 2000 mg/kg bw, Treatment on Day 0 |
SEX: FEMALE |
Cage No. |
Animal Number |
Body weight (g) |
Body Weight Gain (g) |
|||||
0 |
7 |
14 |
0-7 |
7-14 |
0-14 |
|||
1 |
5890 |
244 |
245 |
253 |
1 |
8 |
9 |
|
2 / 1 |
5891 |
246 |
248 |
256 |
2 |
8 |
10 |
|
3 / 1 |
5892 |
238 |
246 |
261 |
8 |
15 |
23 |
|
Mean: |
242.7 |
246.3 |
256.7 |
3.7 |
10.3 |
14.0 |
||
Standard deviation: |
4.2 |
1.5 |
4.0 |
3.8 |
4.0 |
7.8 |
||
Macroscopic FindingsDOSE LEVEL: 2000 mg/kg bw, Treatment on Day 0 |
SEX: FEMALE |
Cage No. |
Animal Number |
Necropsy Date/ Necropsy Day |
External Observations |
Internal Observations |
Organ/Tissue |
1 |
5890 |
27 November 2018 Day 14 |
No external observations recorded |
No internal observations recorded |
Not applicable |
2 / 1 |
5891 |
29 November 2018 Day 14 |
No external observations recorded |
No internal observations recorded |
Not applicable |
3 / 1 |
5892 |
29 November 2018 Day 14 |
No external observations recorded |
No internal observations recorded |
Not applicable |
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 2 000 mg/kg bw
- Quality of whole database:
- K1
Additional information
Acute Toxicity: Oral
The single-dose oral toxicity of AMINOX® was performed according to the acute toxic class method (OECD 423 and Commission Regulation (EC) No 440/2008 of 30 May 2008, B.1.Tris) in CRL:(WI) rats.
Initially, three females (assigned to Group 1) were treated at a dose level of 2000 mg/kg bw. The test item did not cause mortality in this group and a second group (Group 2) was treated at the same dose level. No mortality was observed in the confirmatory group, therefore no further testing was required according to OECD 423 and Commission Regulation (EC) No 440/2008 of 30 May 2008, B.1.tris.
A single oral treatment was carried out by gavage for each animal after an overnight food withdrawal. Food was made available again 3 hours after the treatment. The test item was administered formulated in Dimethyl sulfoxide (DMSO) at a concentration of 200 mg/mL at a dosing volume of 10 mL/kg bw.
Clinical observations were performed at 30 minutes, 1, 2, 3, 4 and 6 hours after dosing and daily for 14 days thereafter. Body weight was measured on Days -1, 0 and 7 and Day 14.
All animals were subjected to a necropsy and a macroscopic examination.
Results
Mortality: AMINOX® did not cause mortality at a dose level of 2000 mg/kg bw.
Clinical Observations: Clinical signs were observed in 3/6 animals treated at the dose level of 2000 mg/kg bw with AMINOX® which included hunched back. There was no other test item related effects on the animals.
Body Weight and Body Weight Gain: One animal at dose level 2000 mg/ kg bw (No: 9632) showed a reduced body weight gain in the second week of the observation period. This change was considered incidental and not ascribed to treatment. There was no other treatment related effects on body weight or body weight gain during the observation period.
Macroscopic Findings: There was no evidence of the macroscopic observations at necropsy at a dose level of 2000 mg/kg bw.
Conclusion: Under the conditions of this study, the acute oral LD50 value of the test item AMINOX® was found to be above 2000 mg/kg bw in female CRL:(WI) rats.
Acute Toxicity: Dermal
An acute dermal toxicity study was performed with the test item AMINOX® in female Crl: WIWistar rats, in compliance with OECD Guideline No.: 402 (2017), Commission Regulation (EC) No 440/2008, B.3 and OPPTS 870.1200 [1-3].
This study was being performed with vertebrate animals as noin vitroalternative is available. The Sponsor confirmed previously that the specific regulatory purpose of this study did not allow a waiving of this dermal acute study, taking account of the OECD guidance document 237.
The study was designed such that the minimum number of animals were used. One female animal was initially treated at a dose level of 2000 mg/kg body weight (bw) in a range-finding phase. Due to the absence of clinical signs, a further 2 females were then treated to confirm the non-lethal dose level. The test item was applied as a single dermal 24-hour exposure followed by a 14-day observation period.
Clinical observations were performed on all animals at 30 minutes, 1, 2, 5 hours after dosing and daily for 14 days thereafter. Body weight was measured on Day 0 (prior to dosing) and on Days 7 and 14 (before necropsy). Gross macroscopic examination was performed on all animals at necropsy at the end of the 14-day observation period (Day 14).
The results of the study were summarised as follows:
Mortality
The test item did not cause mortality at the dose level of 2000 mg/kg bw.
Systemic clinical signs
There were no systemic clinical signs noted in any animal throughout the study.
Local dermal signs
No adverse local dermal signs were observed after treatment with the test item or during the 14-day observation period.
Body weight and body weight gain
There were no test item related effects on body weight or body weight gain during the observation period. Body weights were within the range commonly recorded for this strain and age.
Necropsy
There was no evidence of any macroscopic changes at a dose level of 2000 mg/kg bw.
Conclusions
The acute dermal median lethal dose (LD50) of the test item AMINOX® was found to be greater than 2000 mg/kg body weight in female Crl: WI rats.
According to the GHS criteria, AMINOX® can be ranked as "Unclassified" for acute dermal exposure.
Justification for classification or non-classification
Acute Toxicity: Oral
The test substance is not classified under the CLP criteria.
Acute Toxicity: Dermal
The test substance is not classified under the CLP criteria.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)